Public Health
publicado em 21/01/2013 às 03h16:00
   Dê o seu voto:

Brazil reduces mortality by half early leukemia LPA

The study of network for several countries shows that these indices were hit by Mexico, Chile and Uruguay

 
font size
A-
A+

Some pieces of information on this page may have been automatically translated. Makernews is not responsible for the irregularities resulting from these translations. When in doubt,      consult the original text.



A study on network by developing countries and developed countries shows that, in the past six years, Brazil, Mexico, Chile and Uruguay managed to halve the rate of early mortality of acute promyelocytic leukemia (APL), a more aggressive type of cancer Blood and bone marrow.

For the group's coordinator in Brazil, Eduardo Rego, the Center for Cell Therapy Blood Center of Ribeirão Preto (CTC-HRP), the network cooperation was crucial to the successful outcome and to improve operational controls of cases.

This type of cancer is one of the most aggressive, there is high mortality in the first days after diagnosis, due to very severe hemorrhagic manifestations. Therefore, early diagnosis is very important, and the fact that we can work in consortium allowed us to make the recognition of this form of leukemia in a few hours, which is crucial.

Before the creation of the consortium in 2006, mortality in the first month after diagnosis was above 30% and overall survival after three years was about 50%. In 2011, research showed that the mortality rate dropped to 15% and the survival rate increased to 80%. Rego explained that, in European countries like Spain, early mortality is between 5% to 7% and the survival rate of 90%, where the consortium model is old. We hope to catch up soon.

The oncologist explained that the group was created in 2006 so that developing countries could exchange experiences and data from their patients receive support and reference groups from Europe and the United States. Clinical success in developed countries have been adapted to the peculiarities of each country.

One of the most successful adaptations, the study was the replacement of idarubicin, more substance used to fight the disease in Europe and high cost, by daunorubicin, a substance that is less expensive and more easily found in the Brazilian market. It achieves the same results. The remission rate, ie, healing was similar to that of idarubicin, the medical assured.

Seven other Brazilian institutions participating in the consortium: University of Campinas (Unicamp), Faculty of Medicine, Santa Casa de São Paulo; Hemope Foundation, Pernambuco, and the federal universities of São Paulo, Paraná, Rio Grande do Sul and Minas Gerais . Besides Brazil, part of the international consortium Mexico, Chile, Uruguay, countries in Europe and the United States.

The study was funded solely with public money and, in Brazil, funding was provided by the Foundation for Research Support of the State of São Paulo (FAPESP) and the National Council of Technological and Scientific Development (CNPq).

On Monday (14), the research was published in the journal Blood, the American Society of Hematology, a global benchmark in the art. To the editor-in-chief, Bob Löwenberg, the study raises the level of awareness about the medical problems and encourages cooperation and exchanges between experts experience to adapt to the realities of each country.

This study convincingly demonstrates not in theory but in reality medical care - that you can implement sophisticated treatment experiences in underprivileged areas of the world both in terms of infrastructure with the medical expertise, the editor said.

In Brazil, the unknown incidence of subtypes of the disease compromises the treatment because there are no accurate statistics of LPA. The National Cancer Institute (INCA) predicted last year 4,570 new cases in men and 3,940 in women, but the survey does not distinguish acute from chronic leukemia.

Eduardo Rego says the estimate is that about 20% of acute myeloid leukemias are the type LPA. Insufficient population-based studies clearly indicating that the incidence of acute myeloid leukemia. We still have a major lack of database population, he said.

Source: AGÊNCIA BRASIL
  • Share this pageShare this page
  • Share this pageCorrect
  • ShareShare
  • AlertAlert
Reduced link: 
  • You are recommending this story: Brazil reduces mortality by half early leukemia LPA
  • Fill in the following form to send your recommendation to your friend:

  • You are suggesting a correction for this story: Brazil reduces mortality by half early leukemia LPA


Receba notícias do iSaúde no seu e-mail de acordo com os assuntos de seu interesse.
Seu nome:
Seu email:
Desejo receber um alerta com estes assuntos:
index of early mortality    LPA leukemia    leukemia    early mortality from leukemia LPA    Eduardo Rego    Blood Center of Ribeirão Preto   
Comments:
Comment
Leave your comment
Close
(Required fields are marked with an *)

(Your email address will never be published or shared.)

Enter the letters and numbers below and click in the button "send"

  • Twitter iSaúde
advertising
Informe Saúde printed version

Recommend the portal
Close [X]
  • You are recommending this story: http://www.isaude.net
  • Fill in the following form to send your recommendation to your friend:

RSS news from the portal  iSaúde.net
Get the newsletter of the portal  iSaúde.net
Recommend the portal iSaúde.net
News from  iSaúde.net in your blog or website.
Get news on the subject of your interest.
© 2000-2011 www.isaude.net Todos os direitos reservados.